VL:VH domain rotations in engineered antibodies: Crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs

The crystal structures of two pairs of Fab fragments have been determined. The pairs comprise both a murine and an engineered human form, each derived from the antitumor antibodies A5B7 and CTM01. Although antigen specificity is maintained within the pairs, antigen affinity varies. A comparison of t...

Full description

Saved in:
Bibliographic Details
Published inProteins, structure, function, and bioinformatics Vol. 29; no. 2; pp. 161 - 171
Main Authors Banfield, M.J., King, D.J., Mountain, A., Brady, R.L.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.10.1997
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The crystal structures of two pairs of Fab fragments have been determined. The pairs comprise both a murine and an engineered human form, each derived from the antitumor antibodies A5B7 and CTM01. Although antigen specificity is maintained within the pairs, antigen affinity varies. A comparison of the hypervariable loops for each pair of antibodies shows their structure has been well maintained in grafting, supporting the canonical loop model. Detailed structural analysis of the binding sites and domain arrangements for these antibodies suggests the differences in antigen affinity observed are likely to be due to inherent flexibility of the hypervariable loops and movements at the VL:VH domain interface. The four structures provide the first opportunity to study in detail the effects of protein engineering on specific antibodies. Proteins 29:161–171, 1997. © 1997 Wiley‐Liss, Inc.
Bibliography:ArticleID:PROT4
ark:/67375/WNG-0XNWRWP9-V
BBSRC
Wellcome Trust
istex:F41EF422E7D3EC9D2CAE3449EE1BAC406636F58F
MRC
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0887-3585
1097-0134
DOI:10.1002/(SICI)1097-0134(199710)29:2<161::AID-PROT4>3.0.CO;2-G